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Fluorescence resonance energy transfer (FRET)-based sensors for cAMP and 
PKA allow real-time imaging of cAMP levels and kinase activity in intact cells 
with high spatiotemporal resolution. The development of FRET based sensors 
has made it possible to directly demonstrate that cAMP and PKA signals are 
compartmentalized.  These sensors are currently widely used to dissect the 
organization and physiological function of local cAMP/PKA signaling events in 
a variety of cell systems. Fusion to targeting domains has been used to direct the 
sensors to a specific subcellular nanodomain and to monitor cAMP and PKA 
activity at specific subcellular sites.  Here we investigate the effects of using the 
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A Kinase Anchoring Protein 79 (AKAP79) as a targeting domain for cAMP and 
PKA FRET-based reporters. As AKAP79 interacts with PKA itself, when used 
as a targeting domain it can potentially impact on the amplitude and kinetics of 
the signals recorded locally. By using as the targeting domain wild type AKAP79 
or a mutant that cannot interact with PKA we establish that AKAP79 does not 
affect the amplitude and kinetics of cAMP changes or the level of PKA activity 
detected by the sensor.  
Keywords: Fluorescence Resonance Energy Transfer (FRET), AKAP79, cAMP, 




It is now recognized that signaling by the second messenger 3’-5’cyclic AMP 
(cAMP) is compartmentalized in subcellular nanodomains. Activation of 
different Gs protein coupled receptors leads to elevation of cAMP in distinct and 
confined subcellular sites. This results in activation of limited subsets of PKA 
enzymes which in turn phosphorylate one or more defined protein targets, 
resulting in the appropriate cellular response to the specific extracellular stimulus 
[1]. A kinase anchoring proteins (AKAPs), a family of structurally unrelated 
scaffolding proteins, are localized to different subcellular sites and contribute to 
compartmentalization of signaling by binding PKA and targeting the enzyme in 
proximity of its specific targets [2]. Phosphodiesterases (PDEs) – the enzymes 
that hydrolyze cAMP to AMP – are a large superfamily of metallohydrolases that 
includes over 50 isoforms. PDEs can also be targeted to specific subcellular sites 
by either protein-lipid or protein-protein interactions. At their subcellular anchor 
sites PDEs act as sinks for cAMP thus preventing the homogeneous distribution 
of the second messenger in the cell and contributing to signal 
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compartmentalization [3]. The PKA signal is terminated by phosphatases which 
dephosphorylate PKA targets [4] and, in addition to determining the duration of 
PKA signaling, they can also contribute to compartmentalization by dampening 
the effects of any inappropriate PKA activation that may occur outside the 
relevant nanodomain.  
The development of FRET-based sensors has been instrumental in demonstrating 
compartmentalization of the cAMP/PKA signaling pathway [5-9]. These sensors 
are genetically encoded and can be expressed in living cells, allowing for real 
time imaging of cAMP levels and PKA activity in the intact intracellular 
environment [10]. Fusion of a targeting domain to cAMP or PKA FRET-based 
sensors has been recently used to direct the sensor to a specific subcellular site 
for accurate monitoring of signaling events at that specific nanodomain. This has 
been successfully exploited to study compartmentalization of cAMP [6, 7, 11] 
and PKA activity [8, 12]. For subcellular targeting, a number of investigations 
have relied on fusion of the FRET sensor to AKAPs [9, 13, 14] and most 
commonly AKAP79 [9, 13, 15, 16]. As other AKAPs, AKAP79 contains an 
amphipathic α-helix which binds the dimerization/docking (D/D) domain (amino 
acid 1 to 45) of the PKA RII subunits [17]. AKAP79 also has a plasma membrane 
localization signal that binds to phosphatidylinositol-4, 5 biphosphate (PIP2)[18]. 
AKAP79 forms a complex with multiple signaling molecules. In addition to 
PKA, it interacts with protein kinase C (PKC) [19] and Ca2+ - dependent protein 
phosphatase 2B (PP2B) [4].  In addition, in cardiac mycoytes AKAP79 forms a 
complex with β-adrenergic receptors (β-AR), the adenylyl cyclases 5 and 6 
(AC5/6) and L-type Ca2+ channels (LTCC) [20]. AKAP79-anchored PKA has 
been shown to phosphorylate AC5/6 to dynamically suppress cAMP synthesis 
[21-22]. In addition, AKAP79-anchored PKA has been shown to participate in a 
negative feed-back loop whereby local increase in cAMP activates the anchored 
PKA which in turn phosphorylates and activates long isoforms of PDE4 [23-24]. 
Activated PDE4 more effectively degrades local cAMP leading to reduced PKA 
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activation [15, 25, 26]. Although PDEs do not seem to necessarily interact with 
AKAP directly, PDE4D5 has been suggested to be an essential component of the 
AKAP79-based complex [15, 27, 28]. Given the complexity of the signalosome 
organized by AKAP79, the use of this scaffolding protein for targeting cAMP or 
PKA FRET-based sensors to the plasma membrane may result in disruption of 
the nanodomain as the overexpressed targeted sensor may be expected to bring 
to the targeting site additional kinases and phosphatases that may alter local 
cAMP levels and PKA activity, resulting in artefactual signals. In this study, by 
using a wild type AKAP79 and a mutant version that cannot bind PKA RII [17] 
we investigate the impact of using AKAP79 as a targeting domain on local 
cAMP/PKA signals in neonatal rat cardiac myocytes (NRVM), a cell type that 
expresses endogenous AKAP79 and where AC5/6 and PDE4 are the most 
abundantly expressed adenylyl cyclase and phosphodiesterase isoforms, 
respectively. Our results show that PKA anchoring to AKAP79-targeted sensors 
does not significantly affect the level and kinetics of cAMP nor the PKA activity 
detected locally. 
 
MATERIALS AND METHODS 
 
Site-directed mutagenesis.  
To generate the AKAP79Mut construct, the PKA binding site of the full-length 
AKAP79 protein was mutagenized by introducing leucine to proline substitutions 
in position Leu391 and Leu392 [17] using the site directed mutagenesis kit 
(ThermoFisher Scientific, MA, USA). The forward primer: 5’ – 
GAAACACCCCCAATTGAAACAG - 3’ and the reverse primer:  
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5’- ATATTGTTCTGAAGTTCTATCCTC – 3’ were employed. The mutant 
AKAP79 was cloned in frame at the 5’ end of the CUTie [9] or AKAR4 [29] 
sensor encoded in the pcDNA3.1 vector (Addgene, MA, USA). 
Isolation and culture of cardiomyocytes.  
Neonatal rat ventricular myocytes (NRVMs) from 1-3 days old Sprague Dawley 
rats were cultured and isolated as described [5]. In brief: left ventricles were 
dissociated enzymatically. The cell suspension was then plated on 24-mm glass 
coverslips coated with laminin (20μg/mL). Cells were cultured in growth medium 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% horse 
serum (HS), 5% newborn calf serum (NCS). After 24hrs in culture, the medium 
was replaced with DMEM supplemented with 5% HS and 0.5% NCS. The cells 
were then transiently transfected with TransFectinTM Lipid Reagent (BIOǦRAD 
170Ǧ3351) using 3μg of DNA per well. Efficiency of transfection was about 20%. 
All experiments were performed at 370C, 36-48hrs after transfection in HEPES-
buffered saline supplemented with 1g/L of glucose. 
Pull down experiments and Western Blotting.  
For NRVMs 6x106 cells were plated onto 2x10cm dishes coated with laminin 
(20μg/ml). For transfection 15μg plasmid DNA was mixed with TransFectin 
transfection reagent following manufacturer instructions. 24hrs after transfection, 
the cells were washed with 1xADS buffer (106mM NaCl, 20mM Hepes, 0.8mM 
NaH2PO4, 5.3mM KCl, 0.4mM MgSO4, 5mM glucose),) and lysed for 5 mins 
on ice in Ripa buffer (Sigma-Aldrich, UK) for the samples expressing the 
respective AKAP79-targeted constructs. The lysis buffers were supplemented 
with complete EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics 
Limited, UK) and phosphatase inhibitor tablets. The lysed cells were then 
collected and rotated for 20mins at 4oC. Samples were then centrifuged for 10 
mins at 10,000 rpm at 4oC to remove insoluble material. Total protein was 
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quantified using Micro BCA Protein Assay Kit (Pierce Biotechnology 
Inc.,IL,USA). 500μg of total protein was rotated for 2hrs at 4oC with 25μl of 
agarose beads coated with a monoclonal anti-GFP antibody (GFP-Trap_A, gta-
10, ChromoTek GmbH, DE). Samples were then centrifuged at 2000 rpm for 
1min and supernatant discarded. Beads were washed at least 4 times with ice cold 
Ripa buffer. Bound proteins were eluted in 25μl 2xSDS loading buffer (Life 
technologies) and denatured at 95oC for 5mins. Pulled down proteins were run on 
4-12% Bolt Bis-Tris Plus Gels (ThermoFisher Scientific, MA, USA). The 
proteins were then transferred onto hybond -P, 0.45μm PVDF membrane 
(Amersham, GE Healthcare Life Sciences, UK). After the transfer, the 
membranes were blocked for 1hr at room temperature in 5% skim milk (Sigma 
Aldrich, UK). They were then incubated overnight at 4oC with the following 
antibodies: Adenyl cyclase V/VI (C17) (Santa Cruz Biotechnology, TX, USA at 
1:200), PKA RIIα (Santa Cruz Biotechnology, TX, USA at 1:1000). After at least 
ﬁve washes with TBS-0.5% Tween20 (Alfa Aesar, MA, USA), membranes were 
incubated at room temperature for 1hr with the respective horseradish peroxidase 
conjugated secondary antibodies (at 1:3000) and detected with ECL western 
blotting detection kit (ThermoFisher Scientiﬁc, MA, USA). The blots were 
stripped with stripping buffer (Thermo Fisher Scientiﬁc, MA, USA) and reprobed 
with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (sc-
1666574, Santa Cruz Biotechnology, TX, USA, used at 1:3000). In order to 
control for efficiency of the pull down, an anti-GFP antibody (sc-9996, Santa 
Cruz Biotechnology, TX, USA, at 1:1000) was used.   
FRET Imaging.  
FRET imaging experiments were performed 36–48h after infection of neonatal 
rat ventricular myocytes (NRVM) with pcDNA3.1 vector carrying each targeted 
sensor, as described in [30]. Cells were maintained at room temperature in a 
modiﬁed Ringer solution (140mM NaCl, 3mM KCL, 2mM MgCL2(x 6 H2O), 
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1mM CaCl2(x 2 H2O), 15mM glucose, 10mM Hepes, pH 7.2). An inverted 
microscope (Olympus IX71) with a PlanApoN, 60, NA 1.42 oil immersion 
objective, 0.17/FN 26.5 (Olympus, UK), was used. The microscope was equipped 
with a CoolSNAP HQ2 monochrome camera (Photometrics) and a DV2 optical 
beam-splitter (MAG Biosystems, Photometrics). Images were acquired and 
processed using MetaFluor 7.1, (Meta Imaging Series, Molecular Devices). 
FRET changes were measured as a ratio of the acceptor fluorophore emission 
(545nm) to donor emission (480nm) i.e. 545nm/480nm expressed as R/R0, where 
R is the intensity emission fluorescence ratio at time t and R0 is the average 
emission fluorescence intensity ratio value of the last 8 frames taken before 
addition of the stimulus.   
Statistical Analysis.  
Statistical analysis was performed with GraphPad Prism 5.0. The number of 
technical and biological replicates is indicated in the ﬁgure legends. All groups 
that were statistically compared showed equal variance. Data is presented as 
mean ± s.e.m. One way Anova with Bonferroni’post hoc correction or Student’s 
t-test were used as appropriate. Statistical signiﬁcance, when achieved, is 
indicated as *P≤0.05, **P≤0.01, ***P≤0.001.  
 
RESULTS AND DISCUSSION 
AKAP79 as targeting domain for the cAMP FRET-based sensor CUTie.  
 
AKAP79 binds PKA which, when activated by cAMP, can phosphorylate and 
activate long isoforms of PDE4 [15, 27] and can phosphorylate and inhibit AC5/6 
[21-22] resulting in reduced levels of cAMP. Therefore, overexpression of an 
AKAP79-targeted sensor for cAMP can potentially affect the local level of cAMP 
520589-L-bw-Nshunge
Processed on: 26-6-2018 PDF page: 114








detected and result in an underestimation of the cAMP signal that is generated in 
native conditions at the AKAP79 site. 
To establish whether targeting the cAMP sensor via AKAP79 affects local levels 
of cAMP, we compared the FRET signal detected by the cAMP sensor AKAP79-
CUTie [9] with the signal detected by a variant of this sensor (AKAP79Mut-
CUTie) where the amphipathic helix that binds the D/D domain of the PKA RII 
subunit is disrupted by substituting two leucine for two proline residues (L391P 
and L392P) [17] (Figure 1A). When expressed in neonatal rat ventricular 
myocytes (NRVMs), both AKAP79-CUTie and AKAP79Mut-CUTie showed 
plasma membrane localization as expected (Figure 1B). Loss of RIIα binding to 
AKAP79Mut-CUTie was confirmed by immunoprecipitation of the sensor and 
detection by Western blot analysis of RII in the immunoprecipitate (Figure 1C). 
A band corresponding to the soluble sensor CUTie (~80kDa) was detected in the 
lysates of cells expressing the CUTie-targeted probes (Figure 1C). This may be 
explained by the presence of a putative kozak sequence between the AKAP79 
and the cyclic nucleotide binding domain (CNBD) moieties. Alternatively, it 
could be the consequence of protein degradation. As demonstrated previously for 
AKAP79-CUTie [9], integration of AKAP79Mut-CUTie within the expected 
macromolecular complex at the plasmalemma was confirmed by co-
immunoprecipitation of the sensor and detection of endogenous AC5/6 in the 
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Figure 1. Effect on cAMP readouts by using AKAP79 as a targeting domain for CUTie. A) 
Schematic representation of the targeted CUTie sensor. Stars represent the region where the 
mutations were introduced in AKAP79Mut-CUTie. CNBD is cyclic nucleotide binding domain, CFP 
is cyan fluorescent protein and YFP is yellow fluorescent protein. B) Confocal images showing the 
predominant localization of AKAP79-CUTie and AKAP79Mut-CUTie at the plasmalemma of 
NRVMs. Scale bar is 10μm. C) Western blot analysis showing co-immunoprecipitation of PKA 
RIIα with AKAP79-CUTie and not with AKAP79Mut-CUTie. CUTie, the untargeted cytosolic 
version of the cAMP sensor [9], was used as control. WCL indicates whole cell lysate. D) Western 
blot analysis showing co-immunoprecipitation of AKAP79Mut-CUTie and AC5/6. Ctrl beads 
indicates pulldown with beads without the GFP-trap_A. Representative kinetics (E) and summary 
(F) of FRET change on application of 0.5nM Isoproterenol (Iso) followed by 10μM Rolipram (Roli) 
in NRVMs expressing AKAP79-CUTie (green) and AKAP79Mut-CUTie (red) respectively. Bars in 
F were calculated as relative increase as indicated by the corresponding arrows in E: 1 is Iso 
maximal response; 2 is Iso plateau; 3 is Roli after Iso plateau; 4 is Roli over basal; 5 is saturating 
stimulus (SAT) of 25μM forskolin + 100μM IBMX. G) Summary of the rate of FRET change on 
application of Iso 0.5nM. Representative kinetics (H) and summary (I) of FRET change on 
application of rolipram (Roli) 10μM in absence of β-AR stimulation in NRVMs expressing 
AKAP79-CUTie (green) and AKAP79Mut-CUTie (red), respectively. SAT indicates application of 
saturating stimulus (25μM forskolin + 100μM IBMX). Statistical significance was assessed using 
one way Anova with post hoc correction test except for G where Student’s t-test was used. For all 
experimental sets data are presented as mean ± s.e.m. For all experimental sets N ≥ 15 from at least 
3 biological replicates (independent myocyte isolations). 
 
In order to determine whether anchoring of PKA to AKAP79 may affect the 
amplitude and kinetics of the local cAMP signal, NRVMs expressing either 
AKAP79-CUTie or AKAP79Mut-CUTie were treated with the -adrenergic 
agonist isoproterenol (Iso, 0.5 nM). A transient FRET change on application of 
the stimulus was detected with both sensors and no significant difference was 
apparent in the amplitude of the peak response or in the subsequent plateau level 
(Figure 1E, F).  Similarly, there was no difference in the rate of the FRET change 
detected on application of Iso (Figure 1G). Similar results were found when 
FRET values were averaged over the entire cell or in region of interest drawn in 
correspondence of the plasma membrane, excluding the possibility that the 
fraction of untargeted, soluble CUTie may affect the readings. These results 
indicate that the recruitment of PKA at the plasmalemma on overexpression of 
AKAP79-CUTie does not affect the local cAMP response to -adrenergic 
receptor stimulation.  
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In order to reveal any effect of local PKA recruitment on the extent of PDE4 
activity, the specific PDE4 inhibitor rolipram (10μM) was applied in the presence 
of Iso. As shown in Figure 1E, F, the wild type and mutant sensors detected a 
similar increase in local cAMP level on inhibition of PDE4. AKAP79-CUTie and 
AKAP79Mut-CUTie generated a comparable FRET change also at saturating 
cAMP, as obtained by application of 25 μM forskolin and 100 M IBMX (SAT), 
confirming that the two sensors respond with similar FRET change to maximal 
activation. 
For the experiments described above, NRVM are kept in culture for two days to 
allow expression of the sensor. It is therefore possible that overexpression of the 
AKAP79-targeted reporter and its associated PKA may result in phosphorylation 
of PDE4 during this time in culture. To assess whether overexpression of 
AKAP79-CUTie had an effect on the activity of PDE4 at baseline we measured 
the amplitude of the cAMP response detected by AKAP79-CUTie or 
AKAP79Mut-CUTie on PDE4 inhibition but in the absence of -adrenergic 
stimulus. As shown in Figure 1H, I, application of rolipram (10μM) resulted in a 
similar FRET change for the two sensors. These results indicate that anchoring 
of PKA to the targeting domain AKAP79 has no impact on local cAMP levels. 
 
AKAP79 as a targeting domain for the PKA activity FRET-based sensor 
AKAR4. 
  
We next sought to establish whether anchoring of PKA to the AKAP79 targeting 
domain may affect the level of locally detected PKA mediated phosphorylation.     
For these experiments wild type AKAP79 or the mutant AKAP79 were fused to 
the PKA activity reporter AKAR4 [29] (Figure 2A). Expression of AKAP79-
AKAR4 and AKAP79Mut-AKAR4 in NRVMs showed the expected localization 
at the plasmalemma (Figure 2B). Disruption of PKA RIIα binding to AKAP79Mut-
520589-L-bw-Nshunge
Processed on: 26-6-2018 PDF page: 118








AKAR4 was confirmed by immunoprecipitation of the sensor and detection by 
Western blot analysis of RII in the immunoprecipitate. Results show that while 
AKAP79-AKAR4 co-immunoprecipitates PKA RII, only traces of RII can be 
detected in the AKAP79Mut-AKAR4 immunoprecipitate (Figure 2C). Since 
AKAP79 can dimerize [31], the residual presence of RII subunits in the 
AKAP79Mut-AKAR4 may be due to interaction of the sensor with endogenous 
wildtype AKAP79. The absence of PKA RII in whole cell lysate (Figure 2C) can 
be explained by the fact that only a small fraction of the whole cell lysate was 
loaded for these samples.  
As for the targeted CUTie reporters, untargeted cytosolic AKAR4 (~80kDa) can 
be detected in the lysate of cells expressing AKAP79-targeted AKAR4 sensors 
(Figure 2C), which may be due to the presence of a putative kozak sequence 
between the AKAP79 and the Cerulean moieties. Again, no difference was found 
when comparing FRET values calculated over the entire cell or exclusively at the 
plasma membrane, confirming also in this case that the fraction of cytosolic 
AKAR4 does not impact on the readings. Integration of AKAP79-AKAR4 and 
AKAP79Mut-AKAR4 within the expected macromolecular complex was 
confirmed by co-immunoprecipitation of the respective sensor with endogenous 
AC5/6 (Figure 2D-E).  
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Figure 2: Effect of using AKAP79 as a targeting domain for AKAR4 on detection of PKA activity. 
A) Schematic representation of the targeted AKAR4 sensor. Stars indicate the region where the 
mutations were introduced in AKAP79Mut-AKAR4. FHA1 is the phospho-amino acid binding 
domain. LRRATLVD is the PKA phosphorylation consensus sequence domain. Cerulean is the 
cyan fluorescent protein and YFP is the yellow fluorescent protein. B) Confocal images showing 
the predominant localization of AKAP79-AKAR4 and AKAP79Mut-AKAR4 at the plasmalemma 
of NRVMs. Scale bar is 10μm. C) Western blot analysis showing co-immunoprecipitation of PKA 
RIIα with AKAP79-AKAR4 and AKAP79Mut-AKAR4 in NRVMs. WCL is whole cell lysate. 
AKAR4, a cytosolic version of the PKA activity sensor [29] was used as a control. Western blot 
analysis showing co-immunoprecipitation of AKAP79-AKAR4 (D) and AKAP79Mut-AKAR4 (E) 
with endogenous AC5/6 in NRVMs. Ctrl beads indicates the pulldown with beads without the GFP-
trap_A. Representative kinetics (F) and summary of amplitude (G) of FRET change on application 
of 0.05nM Isoproterenol (Iso) followed by Rolipram (Roli) 10μM in NRVMs expressing either 
AKAP79-AKAR4 (green) or AKAP79Mut-AKAR4 (red). 1 is Iso max; 2 is Iso plateau; 3 is Roli 
max after iso plateau; 4 is Roli plateau over Iso plateau and 5 is saturating stimulus (SAT) of 25μM 
forskolin + 100μM IBMX. H) Summary of the rate of FRET change on application of isoproterenol. 
For experiments shown in F-H, N ≥ 13. Representative kinetics (I) and summary (J) of FRET 
change on application of Roli (10μM) in NRVMs expressing either AKAP79-AKAR4 or 
AKAP79Mut-AKAR4. Striped bar in red represents plateau level of PKA activity reached on decay 
of the signal after the peak response. SAT indicates saturating stimulus (forskolin 25μM + IBMX 
100μM). N ≥ 18. Representative kinetics (K) and summary of amplitude (L) and rate (M) of FRET 
change on application of H89 30μM to otherwise unstimulated cells. N ≥ 12. Representative 
kinetics (N) and summary of amplitude (O) and kinetics (P) of FRET change on application of H89 
30μM after maximal PKA activation in NRVMs expressing AKAP79-AKAR4 (in green) and 
AKAP79Mut-AKAR4 (in red). N ≥ 8. For all data sets, at least 3 biological replicates (independent 
myocyte isolations). For all experimental sets data are presented as mean ± s.e.m. For statistical 
analysis Student’s t-test was used except for G, where one way Anova with post hoc correction test 
was used.  
 
To assess the effect of β-AR stimulation on local PKA activity cells were 
challenged with 0.05 nM Iso. This reduced concentration of agonist was 
necessary to avoid sensor saturation on subsequent application of rolipram and 
saturating stimulus. NRVM expressing either AKAP79-AKAR4 or AKAP79Mut-
AKAR4 showed a similar amplitude (Figure 2F, G) and rate (Fig 2F, H) of FRET 
change on agonist application. In both cases, the majority of cells showed a 
transient response to Iso (90.91% and 84.62% for AKAP79-AKAR4 and 
AKAP79Mut-AKAR4, respectively). The plateau value reached after the peak 
response did not show significant difference between the two sensors. In addition, 
no difference between the increase in PKA-mediated phosphorylation was 
detected when PDE4 was selectively inhibited with rolipram (10μM) after β-AR 
stimulation (Figure 2F, G).  
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To assess any effect of overexpression of the targeted AKAR4 reporters at 
baseline, 10 M rolipram was applied in the absence of other stimuli. As shown 
in Figure 2I, J, no significant difference in the level of PKA activity was apparent 
however, 47% of NRVMs expressing AKAP79Mut-AKAR4 showed a transient 
response to the inhibitor while this was not observed in any of the cells expressing 
AKAP79-AKAR4.   
The transient response on application of rolipram may be explained by higher 
phosphatase activity at baseline in the cells expressing the AKAP79Mut-AKAR4 
sensor. To test this hypothesis, NRVMs expressing AKAP79-AKAR4 or 
AKAP79Mut-AKAR4 were either treated with the PKA inhibitor H89 (30μM) at 
baseline (Figure 2K-M) or with a saturating stimulus before addition of H89 
(30μM) (Figure 2N-P). In the absence of kinase activity, the FRET signal is 
expected to decrease as the sensor is dephosphorylated by phosphatases. As 
shown in Figure 2K-M and Figure 2N-P, there was no statistically significant 
difference in the extent of dephosphorylation of AKAP79-AKAR4 and 
AKAP79Mut-AKAR4, both in terms of amplitude and in terms of rate of 
dephosphorylation. These findings indicate that both at baseline and on maximal 
activation of PKA respectively, the local phosphatase activity is not affected by 
overexpression of AKAP79-AKAR4. A possible explanation for the transient 
response to PDE4 inhibition detected by AKAP79Mut-AKAR4 is that in the 
presence of a small increase in cAMP, as elicited by application of rolipram, local 
phosphatases can more easily counteract the phosphorylation brought about by 
the reduced amount of PKA recruited at AKAP79 complexes in cells expressing 
AKAP79Mut-AKAR4 than in cells expressing AKAP79-AKAR4.  
In conclusion, our studies demonstrate that the ability of AKAP79-targeted 
sensors to locally recruit PKA to AKAP79-specific plasmalemma nanodomains 
does not significantly affect local cAMP/PKA signaling. Therefore, these 
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targeted sensors are expected to accurately report local signals as they happen in 
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